CRMD

CorMedix Inc. (NASDAQ:CRMD) is a biopharmaceutical company founded in 2006 and based in Berkeley Heights, New Jersey. The company was formerly known as Picton Holding Company, Inc. before changing its name to CorMedix, Inc. in January 2007. After years of clinical development and regulatory challenges, CorMedix achieved a major milestone in 2024 when it successfully launched its flagship product DefenCath commercially, transitioning from a pre-revenue development-stage company to a profitable commercial enterprise. The company focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases, with particular expertise in catheter-related infections.